ATE486937T1 - Chimärische heteromultimerische adhesine - Google Patents

Chimärische heteromultimerische adhesine

Info

Publication number
ATE486937T1
ATE486937T1 AT97932526T AT97932526T ATE486937T1 AT E486937 T1 ATE486937 T1 AT E486937T1 AT 97932526 T AT97932526 T AT 97932526T AT 97932526 T AT97932526 T AT 97932526T AT E486937 T1 ATE486937 T1 AT E486937T1
Authority
AT
Austria
Prior art keywords
adhesins
chimeric
heteromultimeric
erbb2
heteromultimer
Prior art date
Application number
AT97932526T
Other languages
English (en)
Inventor
Vincent Fizpatrick
Mark Sliwkowski
Richard Vandlen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE486937T1 publication Critical patent/ATE486937T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Adhesives Or Adhesive Processes (AREA)
AT97932526T 1996-07-12 1997-07-08 Chimärische heteromultimerische adhesine ATE486937T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2164096P 1996-07-12 1996-07-12
US79832697A 1997-02-10 1997-02-10
PCT/US1997/011825 WO1998002540A1 (en) 1996-07-12 1997-07-08 Chimeric heteromultimer adhesins

Publications (1)

Publication Number Publication Date
ATE486937T1 true ATE486937T1 (de) 2010-11-15

Family

ID=26694954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97932526T ATE486937T1 (de) 1996-07-12 1997-07-08 Chimärische heteromultimerische adhesine

Country Status (13)

Country Link
US (3) US6696290B2 (de)
EP (2) EP0938556B1 (de)
JP (2) JP4274581B2 (de)
CN (1) CN1202247C (de)
AT (1) ATE486937T1 (de)
AU (1) AU722178B2 (de)
BR (1) BR9710357A (de)
CA (1) CA2258721C (de)
DE (1) DE69740038D1 (de)
DK (1) DK0912734T3 (de)
IL (1) IL127891A0 (de)
NZ (1) NZ333325A (de)
WO (1) WO1998002540A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053256B9 (de) * 1998-01-26 2012-01-18 Genentech, Inc. Antikörper gegen "death receptor 4" (dr4) und deren verwendungen
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (de) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Zusammensetzungen und Verfahren zur Behandlung von Tumoren
DE69939374D1 (de) * 1998-03-17 2008-10-02 Genentech Inc Zu vegf und bmp1 homologe polypeptide
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
EP2177616B1 (de) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003012045A2 (en) * 2001-07-31 2003-02-13 Wayne State University Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
EP1283053A1 (de) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitore der HER3 Aktivität
US7919098B2 (en) * 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
EA010055B1 (ru) * 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
CA2558811A1 (en) * 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
KR101239542B1 (ko) * 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
DE602005022475D1 (de) 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
NZ598421A (en) * 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
KR20090057936A (ko) * 2006-02-08 2009-06-08 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 2가 ｅｒｂｂ 리간드 결합 분자 및 그의 제조 방법 및 사용방법
CN101611150A (zh) * 2006-02-08 2009-12-23 利佳赛普特有限责任公司 二价ErbB配体结合分子及其制备和使用方法
CA2643478C (en) 2006-02-23 2019-06-18 Novocell, Inc. Compositions and methods useful for culturing differentiable cells
AU2007257683A1 (en) * 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2647388A1 (de) 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antikörper gegen ERBB3 und Verwendungen davon
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
WO2009052184A2 (en) * 2007-10-16 2009-04-23 Receptor Biologix, Inc. Compositions comprising optimized her1 and her3 multimers and methods of use thereof
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
CN102099377A (zh) * 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
PE20120015A1 (es) 2008-08-15 2012-01-26 Merrimack Pharmaceuticals Inc Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
EP2346526A2 (de) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Zusammensetzungen und verfahren zur verwendung von liganden-dimeren
AU2009324939B2 (en) 2008-11-25 2015-07-09 Genentech, Inc. Isoform specific anti-HER4 antibodies
JP5926680B2 (ja) * 2009-07-28 2016-05-25 リガセプト・エルエルシー 広範囲のＥｒｂＢリガンド結合分子ならびにそれを調製および使用するための方法
MX2012008958A (es) 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012103114A2 (en) * 2011-01-24 2012-08-02 Jason Hill Therapeutic chimeric ligand binding proteins and methods for their use
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
EP3693381A1 (de) 2013-02-18 2020-08-12 Vegenics Pty Limited Ligandbindende moleküle und verwendungen davon
AU2014285079A1 (en) 2013-07-05 2016-01-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble CD33 for treating myelodysplastic syndromes (MDS)
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3242893A1 (de) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
KR20180117529A (ko) 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
WO2019132517A1 (ko) * 2017-12-26 2019-07-04 주식회사 프로티나 세포 내 또는 세포 간 단백질-단백질 상호작용 분석 방법 및 장치
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
WO1990006953A2 (en) 1988-12-22 1990-06-28 Genentech, Inc. Method for preparing water soluble polypeptides
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (de) 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: Ein neues EGF-Rezeptor Homologes
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5254536A (en) * 1992-01-10 1993-10-19 The Du Pont Merck Pharmaceutical Company Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE69408541T2 (de) 1993-11-23 1998-08-06 Genentech Inc Kinaserezeptoraktivierungstest
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides

Also Published As

Publication number Publication date
AU722178B2 (en) 2000-07-27
EP0938556A1 (de) 1999-09-01
DE69740038D1 (de) 2010-12-16
DK0912734T3 (da) 2011-02-07
AU3596297A (en) 1998-02-09
CN1225129A (zh) 1999-08-04
WO1998002540A1 (en) 1998-01-22
US7659368B2 (en) 2010-02-09
BR9710357A (pt) 1999-08-17
US20040138417A1 (en) 2004-07-15
IL127891A0 (en) 1999-10-28
US6696290B2 (en) 2004-02-24
CA2258721C (en) 2014-09-09
EP0912734B1 (de) 2010-11-03
EP0938556B1 (de) 2005-03-09
CN1202247C (zh) 2005-05-18
US20030199020A1 (en) 2003-10-23
JP4274581B2 (ja) 2009-06-10
US20070081994A1 (en) 2007-04-12
JP2008115187A (ja) 2008-05-22
JP2000515372A (ja) 2000-11-21
EP0912734A1 (de) 1999-05-06
CA2258721A1 (en) 1998-01-22
NZ333325A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
ATE486937T1 (de) Chimärische heteromultimerische adhesine
DE69732711D1 (de) Gamma-heregulin
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
NZ516258A (en) Tek antagonists
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
MA32449B1 (fr) Agents de liaison de notch et antagonistes de notch ainsi que procedes d'utilisation correspondants
DE69942753D1 (de) Peptidantagonist von Zonulin und dessen Verwendung
DE69129990T2 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
EP1017713A4 (de) ZYKLISCHE AGONISTEN UND ANTAGONISTEN DER C5a REZEPTOREN SOWIE G-PROTEIN GEKOPPELTEN REZEPTOREN
MX9604316A (es) Anticuerpos agonistas de la proteina tirosina cinasa.
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
DE60030769D1 (de) Verfahren zur behandlung von entzündungen
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
DE69637570D1 (de) Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung
SE9704836D0 (sv) Novel receptor
BG104268A (en) Bitumen or asphalt for producing road surfacing, road surfacing and method for the preparation of bitumen or asphalt
NZ329807A (en) NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
EA200700951A1 (ru) БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
DE69333660D1 (de) Pct-65 serotonin rezeptor
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
EP0858505A4 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
MX9603045A (es) Antagonistas de los receptores endoteliales.
NO975565L (no) Benstimulerende faktor
MX9603199A (es) Antagonistas de receptores a endotelina.
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties